Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s40880-018-0319-7 http://scihub22266oqcxt.onion/10.1186/s40880-018-0319-7 C6062982!6062982!30053908     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Commun+(Lond) 2018 ; 38 (ä): ä Nephropedia Template TP {{tp|p=30053908|t=2018. Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways |pdf=|usr=}}{{30053908}} gab.com Text Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways JO: Cancer Commun (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=30053908 #FOAvip Background: In previous studies, we have shown that the combination of metformin and gefitinib inhibits the growth of bladder cancer cells. Here we examined whether the metformin analogue phenformin, either used alone or in combination with gefitinib, could inhibit growth of bladder cancer cells. Methods: The growth-inhibitory effects of phenformin and gefitinib were tested in one murine and two human bladder cancer cell lines using MTT and clonogenic assays. Effects on cell migration were assessed in a wound healing assay. Synergistic action between the two drugs was assessed using CompuSyn software. The potential involvement of AMPK and EGFR pathways in the effects of phenformin and gefitinib was explored using Western blotting. Results: In MTT and clonogenic assays, phenformin was >?10-fold more potent than metformin in inhibiting bladder cancer cell growth. Phenformin also potently inhibited cell migration in wound healing assays, and promoted apoptosis. AMPK signaling was activated; EGFR signaling was inhibited. Phenformin was synergistic with gefitinib, with the combination of drugs showing much stronger anticancer activity and apoptotic activation than phenformin alone. Conclusions: Phenformin shows potential as an effective drug against bladder cancer, either alone or in combination with gefitinib. Twit Text FOAVip Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways ????Cancer Commun (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=30053908 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30053908 #FOAvip English Wikipedia <ref>{{Cite pmid|30053908}}</ref> Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways #MMPMID30053908 Huang Y; Zhou S; He C; Deng J; Tao T; Su Q; Darko KO; Peng M; Yang X Cancer Commun (Lond) 2018[]; 38 (ä): ä PMID30053908show ga Background: In previous studies, we have shown that the combination of metformin and gefitinib inhibits the growth of bladder cancer cells. Here we examined whether the metformin analogue phenformin, either used alone or in combination with gefitinib, could inhibit growth of bladder cancer cells. Methods: The growth-inhibitory effects of phenformin and gefitinib were tested in one murine and two human bladder cancer cell lines using MTT and clonogenic assays. Effects on cell migration were assessed in a wound healing assay. Synergistic action between the two drugs was assessed using CompuSyn software. The potential involvement of AMPK and EGFR pathways in the effects of phenformin and gefitinib was explored using Western blotting. Results: In MTT and clonogenic assays, phenformin was >?10-fold more potent than metformin in inhibiting bladder cancer cell growth. Phenformin also potently inhibited cell migration in wound healing assays, and promoted apoptosis. AMPK signaling was activated; EGFR signaling was inhibited. Phenformin was synergistic with gefitinib, with the combination of drugs showing much stronger anticancer activity and apoptotic activation than phenformin alone. Conclusions: Phenformin shows potential as an effective drug against bladder cancer, either alone or in combination with gefitinib. äPhenformin alone or combined with gefitinib inhibits bladder cancer vi(epmc).pdf DeepDyve Pubget Overpricing